Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?
Year: 2021
Type: review
Abstract: This article provides a brief overview of drug resistance to antiviral therapy as well as known and emergent variability in key SARS-CoV-2 viral sequences. The purpose is to stimulate deliberation about the need to consider drug resistance prior to widespread roll-out of antivirals for SARS-CoV-2. Many existing candidate agents have mechanisms of action involving drug targets likely to be critical for future drug development. Resistance emerged quickly with monotherapies deployed for other pulmonary viruses such as influenza virus, and in HIV mutations in key drug targets compromised efficacy of multiple drugs within a class. The potential for drug resistance in SARS-CoV-2 has not yet been rigorously debated or assessed, and we call for more academic and industry research on this potentially important future threat prior to widespread roll-out of monotherapies for COVID-19 treatment and prevention.
DOI: 10.1093/jac/dkab189
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Wellcome Trust, UK Research and Innovation, European Commission, National Institutes of Health, Medical Research Council, Engineering and Physical Sciences Research Council, Biotechnology and Biological Sciences Research Council, Innovate UK, National Institute of Allergy and Infectious Diseases, Unitaid
Awards: AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment, G2341205921, G2400908033, Long acting NRTI therapies for HIV, G3745968079, China Partnering Award: Exchange of vaccine technology for delivery of oral vaccines to mucosal surfaces, The role of LC3-associated phagocytosis during virus infection, BPIFA1: from anti-viral peptide to immunomodulator, New Branched Polymers Excipients and Emulsions for Enhanced Drug Delivery, An Injectable Implant Providing Long-Acting Drug Delivery for the Treatment of Chronic disease, Regulatory Science Framework for Nano(bio)material-based Medical Products and Devices, G697565132, Targeting the RNA helicase, UAP56: understanding KSHV RNA processing mechanisms to novel antiviral approaches, G7620128503, AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment, G8817154565, The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)
OpenAlex ID: W3171409443